APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroleptic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuroleptic Market Outlook and Growth Opportunities 2026

26 December 2025198 pages

Choose your research edition.

Industry ResearchNeuroleptic Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroleptic Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Neuroleptic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroleptic Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroleptic Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Neuroleptic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuroleptic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuroleptic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroleptic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuroleptic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuroleptic market include Johnson & Johnso, Eli Lilly, Pfizer, GlaxoSmithKline and Bristol-Myers Squibb, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuroleptic market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuroleptic and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuroleptic sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuroleptic market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuroleptic Segment by Company

Johnson & Johnso

Eli Lilly

Pfizer

GlaxoSmithKline

Bristol-Myers Squibb

Neuroleptic Segment by Type

Droperidol

Midazolam

Neuroleptic Segment by Application

Medical Care

Scientific Research

Others

Neuroleptic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Neuroleptic status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuroleptic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuroleptic significant trends, drivers, influence factors in global and regions.

6. To analyze Neuroleptic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroleptic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroleptic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroleptic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuroleptic market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuroleptic industry.

Chapter 3: Detailed analysis of Neuroleptic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuroleptic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuroleptic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuroleptic Industry Trends Table 2. Neuroleptic Industry Drivers Table 3. Neuroleptic Industry Opportunities and Challenges Table 4. Neuroleptic Industry Restraints Table 5. Global Neuroleptic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuroleptic Revenue Share by Company (2021-2026) Table 7. Global Neuroleptic Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Neuroleptic Sales Volume Share by Company (2021-2026) Table 9. Global Neuroleptic Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Neuroleptic Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuroleptic Key Company Manufacturing Base & Headquarters Table 12. Global Neuroleptic Company, Product Type & Application Table 13. Global Neuroleptic Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuroleptic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Droperidol Table 18. Significant Companies of Midazolam Table 19. Global Neuroleptic Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Neuroleptic Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Neuroleptic Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Neuroleptic Sales Volume Share by Type (2021-2026) Table 23. Global Neuroleptic Sales Volume Share by Type (2027-2032) Table 24. Global Neuroleptic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Neuroleptic Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Neuroleptic Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Neuroleptic Sales Value Share by Type (2021-2026) Table 28. Global Neuroleptic Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Medical Care Table 30. Significant Companies of Scientific Research Table 31. Significant Companies of Others Table 32. Global Neuroleptic Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Neuroleptic Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Neuroleptic Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Neuroleptic Sales Volume Share by Application (2021-2026) Table 36. Global Neuroleptic Sales Volume Share by Application (2027-2032) Table 37. Global Neuroleptic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Neuroleptic Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Neuroleptic Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Neuroleptic Sales Value Share by Application (2021-2026) Table 41. Global Neuroleptic Sales Value Share by Application (2027-2032) Table 42. Global Neuroleptic Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Neuroleptic Sales by Region (2021-2026) & (K Units) Table 44. Global Neuroleptic Sales Market Share by Region (2021-2026) Table 45. Global Neuroleptic Sales by Region (2027-2032) & (K Units) Table 46. Global Neuroleptic Sales Market Share by Region (2027-2032) Table 47. Global Neuroleptic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Neuroleptic Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Neuroleptic Sales Value Share by Region (2021-2026) Table 50. Global Neuroleptic Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Neuroleptic Sales Value Share by Region (2027-2032) Table 52. Global Neuroleptic Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Neuroleptic Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Neuroleptic Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Neuroleptic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Neuroleptic Sales by Country (2021-2026) & (K Units) Table 57. Global Neuroleptic Sales Market Share by Country (2021-2026) Table 58. Global Neuroleptic Sales by Country (2027-2032) & (K Units) Table 59. Global Neuroleptic Sales Market Share by Country (2027-2032) Table 60. Global Neuroleptic Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Neuroleptic Sales Value Market Share by Country (2021-2026) Table 62. Global Neuroleptic Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Neuroleptic Sales Value Market Share by Country (2027-2032) Table 64. Johnson & Johnso Company Information Table 65. Johnson & Johnso Business Overview Table 66. Johnson & Johnso Neuroleptic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Johnson & Johnso Neuroleptic Product Portfolio Table 68. Johnson & Johnso Recent Development Table 69. Eli Lilly Company Information Table 70. Eli Lilly Business Overview Table 71. Eli Lilly Neuroleptic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Eli Lilly Neuroleptic Product Portfolio Table 73. Eli Lilly Recent Development Table 74. Pfizer Company Information Table 75. Pfizer Business Overview Table 76. Pfizer Neuroleptic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Pfizer Neuroleptic Product Portfolio Table 78. Pfizer Recent Development Table 79. GlaxoSmithKline Company Information Table 80. GlaxoSmithKline Business Overview Table 81. GlaxoSmithKline Neuroleptic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline Neuroleptic Product Portfolio Table 83. GlaxoSmithKline Recent Development Table 84. Bristol-Myers Squibb Company Information Table 85. Bristol-Myers Squibb Business Overview Table 86. Bristol-Myers Squibb Neuroleptic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Bristol-Myers Squibb Neuroleptic Product Portfolio Table 88. Bristol-Myers Squibb Recent Development Table 89. Key Raw Materials Table 90. Raw Materials Key Suppliers Table 91. Neuroleptic Distributors List Table 92. Neuroleptic Customers List Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Neuroleptic Product Image Figure 2. Global Neuroleptic Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroleptic Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuroleptic Sales (2021-2032) & (K Units) Figure 5. Global Neuroleptic Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Neuroleptic Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Droperidol Image Figure 10. Midazolam Image Figure 11. Global Neuroleptic Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Neuroleptic Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Neuroleptic Sales Volume Share by Type (2021-2032) Figure 14. Global Neuroleptic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Neuroleptic Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Neuroleptic Sales Value Share by Type (2021-2032) Figure 17. Medical Care Image Figure 18. Scientific Research Image Figure 19. Others Image Figure 20. Global Neuroleptic Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Neuroleptic Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Neuroleptic Sales Volume Share by Application (2021-2032) Figure 23. Global Neuroleptic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Neuroleptic Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Neuroleptic Sales Value Share by Application (2021-2032) Figure 26. Global Neuroleptic Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Neuroleptic Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Neuroleptic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Neuroleptic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Neuroleptic Sales Value (2021-2032) & (US$ Million) Figure 31. North America Neuroleptic Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Neuroleptic Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Neuroleptic Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Neuroleptic Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Neuroleptic Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Neuroleptic Sales Value (2021-2032) & (US$ Million) Figure 37. South America Neuroleptic Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Neuroleptic Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Neuroleptic Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Neuroleptic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Neuroleptic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Neuroleptic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Neuroleptic Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Neuroleptic Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Droperidol
  • Midazolam
Applications
  • Medical Care
  • Scientific Research
  • Others
Companies covered
  • Johnson & Johnso
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroleptic Sales Value (2021-2032)
  4. 1.2.2 Global Neuroleptic Sales Volume (2021-2032)
  5. 1.2.3 Global Neuroleptic Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuroleptic Market Dynamics
  1. 2.1 Neuroleptic Industry Trends
  2. 2.2 Neuroleptic Industry Drivers
  3. 2.3 Neuroleptic Industry Opportunities and Challenges
  4. 2.4 Neuroleptic Industry Restraints
3 Neuroleptic Market by Company
  1. 3.1 Global Neuroleptic Company Revenue Ranking in 2025
  2. 3.2 Global Neuroleptic Revenue by Company (2021-2026)
  3. 3.3 Global Neuroleptic Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuroleptic Average Price by Company (2021-2026)
  5. 3.5 Global Neuroleptic Company Ranking (2024-2026)
  6. 3.6 Global Neuroleptic Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuroleptic Company Product Type and Application
  8. 3.8 Global Neuroleptic Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuroleptic Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuroleptic Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuroleptic Market by Type
  1. 4.1 Neuroleptic Type Introduction
  2. 4.1.1 Droperidol
  3. 4.1.2 Midazolam
  4. 4.2 Global Neuroleptic Sales Volume by Type
  5. 4.2.1 Global Neuroleptic Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Neuroleptic Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Neuroleptic Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Neuroleptic Sales Value by Type
  9. 4.3.1 Global Neuroleptic Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Neuroleptic Sales Value by Type (2021-2032)
  11. 4.3.3 Global Neuroleptic Sales Value Share by Type (2021-2032)
5 Neuroleptic Market by Application
  1. 5.1 Neuroleptic Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Scientific Research
  4. 5.1.3 Others
  5. 5.2 Global Neuroleptic Sales Volume by Application
  6. 5.2.1 Global Neuroleptic Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroleptic Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Neuroleptic Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Neuroleptic Sales Value by Application
  10. 5.3.1 Global Neuroleptic Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Neuroleptic Sales Value by Application (2021-2032)
  12. 5.3.3 Global Neuroleptic Sales Value Share by Application (2021-2032)
6 Neuroleptic Regional Sales and Value Analysis
  1. 6.1 Global Neuroleptic Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuroleptic Sales by Region (2021-2032)
  3. 6.2.1 Global Neuroleptic Sales by Region: 2021-2026
  4. 6.2.2 Global Neuroleptic Sales by Region (2027-2032)
  5. 6.3 Global Neuroleptic Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuroleptic Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuroleptic Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuroleptic Sales Value by Region (2027-2032)
  9. 6.5 Global Neuroleptic Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuroleptic Sales Value (2021-2032)
  12. 6.6.2 North America Neuroleptic Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuroleptic Sales Value (2021-2032)
  15. 6.7.2 Europe Neuroleptic Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuroleptic Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuroleptic Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuroleptic Sales Value (2021-2032)
  21. 6.9.2 South America Neuroleptic Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuroleptic Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuroleptic Sales Value Share by Country, 2025 VS 2032
7 Neuroleptic Country-level Sales and Value Analysis
  1. 7.1 Global Neuroleptic Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuroleptic Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuroleptic Sales by Country (2021-2032)
  4. 7.3.1 Global Neuroleptic Sales by Country (2021-2026)
  5. 7.3.2 Global Neuroleptic Sales by Country (2027-2032)
  6. 7.4 Global Neuroleptic Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuroleptic Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuroleptic Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuroleptic Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuroleptic Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuroleptic Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuroleptic Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuroleptic Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuroleptic Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuroleptic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuroleptic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuroleptic Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuroleptic Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuroleptic Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuroleptic Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuroleptic Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuroleptic Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuroleptic Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuroleptic Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuroleptic Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuroleptic Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuroleptic Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuroleptic Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuroleptic Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuroleptic Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuroleptic Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuroleptic Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuroleptic Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuroleptic Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuroleptic Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuroleptic Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuroleptic Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuroleptic Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuroleptic Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuroleptic Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuroleptic Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuroleptic Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuroleptic Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuroleptic Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuroleptic Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuroleptic Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuroleptic Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuroleptic Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuroleptic Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuroleptic Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuroleptic Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuroleptic Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuroleptic Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuroleptic Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuroleptic Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuroleptic Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuroleptic Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuroleptic Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuroleptic Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuroleptic Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuroleptic Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuroleptic Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuroleptic Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuroleptic Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuroleptic Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuroleptic Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuroleptic Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuroleptic Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuroleptic Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuroleptic Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuroleptic Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuroleptic Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuroleptic Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuroleptic Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuroleptic Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuroleptic Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuroleptic Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuroleptic Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuroleptic Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuroleptic Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuroleptic Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuroleptic Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuroleptic Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuroleptic Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuroleptic Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuroleptic Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuroleptic Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuroleptic Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuroleptic Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuroleptic Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuroleptic Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuroleptic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnso
  2. 8.1.1 Johnson & Johnso Company Information
  3. 8.1.2 Johnson & Johnso Business Overview
  4. 8.1.3 Johnson & Johnso Neuroleptic Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnso Neuroleptic Product Portfolio
  6. 8.1.5 Johnson & Johnso Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly Neuroleptic Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly Neuroleptic Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Neuroleptic Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Neuroleptic Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Neuroleptic Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Neuroleptic Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 Bristol-Myers Squibb
  26. 8.5.1 Bristol-Myers Squibb Company Information
  27. 8.5.2 Bristol-Myers Squibb Business Overview
  28. 8.5.3 Bristol-Myers Squibb Neuroleptic Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bristol-Myers Squibb Neuroleptic Product Portfolio
  30. 8.5.5 Bristol-Myers Squibb Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuroleptic Value Chain Analysis
  2. 9.1.1 Neuroleptic Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuroleptic Sales Mode & Process
  6. 9.2 Neuroleptic Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuroleptic Distributors
  9. 9.2.3 Neuroleptic Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst